新冠疫情对近距离放疗的影响:Rutgers-Robert Wood Johnson Barnabas Health多中心经验
本研究回顾性分析了4个附属中心在2020年2月24日至6月30日期间接受近距离放疗的47例癌症患者,评估疫情导致的治疗延迟、取消和方案调整。结果显示多数患者治疗安全,但部分出现延迟和中断,需长期随访评估对肿瘤结局的影响。
要点
- 47例患者中,8例(17%)近距离放疗取消,9例(19%)因COVID-19治疗延迟。
- 发生治疗中断者平均延迟16.3天,中位延迟14天。
- 宫颈癌患者总治疗时间平均56天,中位49天。
核心结论
- 尽管疫情带来挑战,多数癌症患者仍安全接受近距离放疗,仅出现轻微延迟和中断。
- 需长期随访评估COVID-19及治疗中断对肿瘤结局的影响。
研究设计与样本
- 回顾性队列研究,经当地机构审查委员会批准,在4个附属中心开展。
- 纳入2020年2月24日至2020年6月30日疫情期间治疗计划包含近距离放疗的所有癌症患者,共47例。
- 评估治疗延迟、取消、分次方案调整及治疗模式变化。
主要发现
- 患者治疗时中位年龄62岁(四分位距56-70岁)。
- 子宫内膜癌、宫颈癌和前列腺癌是最常见的 included 部位。
- 3例(6.4%)宫颈癌患者在治疗期间诊断为COVID-19。
- 外照射放疗中断、外照射取消、近距离放疗取消及因COVID-19治疗延迟分别发生于5例(10.6%)、3例(6.4%)、8例(17%)和9例(19%)患者。
- 发生治疗中断者平均延迟16.3天(标准差13.9天),中位延迟14天(四分位距5.75-23.75天)。
临床怎么用
- 疫情期间可对多数癌症患者安全实施近距离放疗,但需关注治疗延迟和中断。
- 对宫颈癌等需连续治疗的患者,应监测总治疗时间。
局限性
- 样本量较小(47例),为回顾性研究。
- 未报告长期肿瘤结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to evaluate whether the coronavirus disease of 2019 (COVID-19) pandemic resulted in treatment delays in patients scheduled for or undergoing brachytherapy. METHODS AND MATERIALS: A retrospective cohort study was conducted across 4 affiliated sites after local institutional review board approval. The eligibility criteria were defined as all patients with cancer whose treatment plan included brachytherapy during the COVID-19 pandemic from February 24, 2020 to June 30, 2020. Treatment delays, cancellations, alterations of fractionation regimens, and treatment paradigm changes were evaluated. RESULTS: A total of 47 patients were eligible for the analysis. Median patient age at the time of treatment was 62 years (interquartile range, 56-70 years). Endometrial, cervical, and prostate cancers were the most common sites included in this analysis. Three patients (6.4%) with cervical cancer were diagnosed with COVID-19 during the course of their treatment. Interruptions of external beam radiation therapy (EBRT), cancellations of EBRT, cancellations of brachytherapy, and treatment delays due to COVID occurred in 5 (10.6%), 3 (6.4%), 8 (17%), and 9 (19%) patients, respectively. The mean and median number of days delayed for patients who experienced treatment interruptions were 16.3 days (standard deviation: 13.9 days) and 14 days (interquartile range, 5.75-23.75 days), respectively. For patients with cervical cancer, the mean and median overall treatment times defined as the time from the start of EBRT to the end of brachytherapy were 56 and 49 days, respectively. CONCLUSIONS: Despite the challenges the health care system faced during the pandemic, most patients with cancer were safely treated with minor treatment delays and interruptions. Long-term follow up is needed to assess the impact of COVID-19 and treatment interruptions on oncologic outcomes.
引用
- Hathout L, Ennis RD, Mattes MD, et al. The Impact of COVID-19 on Brachytherapy During the Pandemic: A Rutgers-Robert Wood Johnson Barnabas Health Multisite Experience. Adv Radiat Oncol. 2020. PMID: 33163697. doi:10.1016/j.adro.2020.10.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。